The noninvasive functional characterization of the cardiac sympathetic nervous system by imaging techniques may provide important pathophysiological information in various cardiac disease states. Hydroxyephedrine labeled with carbon 11 has been developed as a new catecholamine analogue to be used in the in vivo evaluation of presynaptic adrenergic nerve terminals by positron emission tomography (PET). To determine the feasibility of this imaging approach in the human heart, six normal volunteers and five patients with recent cardiac transplants underwent dynamic PET imaging after intravenous injection of 20 mCi [11C]hydroxyephedrine. Blood and myocardial tracer kinetics were assessed using a regionsof-interest approach. In normal volunteers, blood`1C activity cleared rapidly, whereas myocardium retained`1C activity with a long tissue half-life. Relative tracer retention in the myocardium averaged 79+±31% of peak activity at 60 minutes after tracer injection. The heart-to-blood`1C activity ratio exceeded 6:1 as soon as 30 minutes after tracer injection, yielding excellent image quality. Little regional variation of tracer retention was observed, indicating homogeneous sympathetic innervation throughout the left ventricle. In the transplant recipients, myocardial [11C]hydroxyephedrine retention at 60 minutes was significantly less (-82%) than that of normal volunteers, indicating only little non-neuronal binding of the tracer in the denervated human heart. Thus, [11C]hydroxyephedrine, in combination with dynamic PET imaging, allows the noninvasive delineation of myocardial adrenergic nerve terminals. Tracer kinetic modeling may permit quantitative assessment of myocardial catecholamine uptake, which will in turn provide insights into the effects of various disease processes on the neuronal integrity of the heart. (Circulation 1990;82:457-464) T he role of the sympathetic nervous system in the pathophysiology of congestive heart failure and dysrhythmia is being increasingly recognized.1-4 Clinical and animal studies have linked the heterogeneity of sympathetic innervation after myocardial ischemia to the increased incidence of sudden death in patients with coronary artery disease.1,2,5,6 In patients with congestive heart failure, there is evidence
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Positron emission tomography (PET) is an improved imaging technology that permits the regional quantification of tracer concentration in tissue. 12 In addition, labeling of compounds with short-lived radionuclides such as carbon-11 or fluorine-18 allows the administration of relatively large tracer doses, yielding superior image quality.13 ['1C]Hydroxyephedrine has been developed in our laboratory as a new norepinephrine analogue.14 Animal experiments indicate that there is a highly specific uptake and retention of this tracer in sympathetic nerve terminals, with little non-neuronal binding.15 Tracer retention after intravenous injection of ["C]hydroxyephedrine correlates closely with regional tissue norepinephrine concentration in a canine model of regional denervation.15 Based on these encouraging results, the radiosynthesis of [1C]hydroxyephedrine has been refined for clinical applications.
The purpose of this study was to assess the feasibility of this new tracer approach for the noninvasive evaluation of the sympathetic nervous system of the human heart. The blood and myocardial kinetics of [1"C]hydroxyephedrine were determined by dynamic PET imaging in normal volunteers and in patients with recent cardiac transplants who served as a clinical model of global cardiac denervation.
Methods

Subjects
Six healthy volunteers with a mean age of 23 ± 7 years were studied. The presence of cardiac disease was excluded by history, physical examination, and resting electrocardiogram. None of the subjects were taking any cardiac or noncardiac medication at the time of the study.
In addition to these normal volunteers, five patients with recent (5.3 ±3.0 months) cardiac transplants were selected from a pool of heart transplant recipients at the University of Michigan Medical Center. The clinical status of these individuals was stable with no evidence of transplant rejection. All transplant patients received immunosuppressive therapy consisting of cyclosporine, immurane, and steroids. None of the patients was taking any medication known to interfere with norepinephrine uptake by sympathetic nerve terminals. All of the individuals participating in this study signed an informed consent form approved by the institutional committee for clinical research before consideration for evaluation by PET.
Radiosynthesis of ["C]Hydroxyephedrine
[1C]Hydroxyephedrine was synthesized by direct Nmethylation of metaraminol with ['1C]methyl iodide in DMF-DMSO and purified by preparative reversephase high-performance liquid chromatography (HPLC) in an isotonic buffered aqueous system with direct formulation after filter sterilization. 16 The chemical structure of ["C]hydroxyephedrine is shown in radiochemical yield with a specific activity of more than 1,000 Ci/mmol at the end of synthesis (>4,500 Ci/mmol at end of bombardment). Typical radiochemical and chemical purities of the final tracer were 95% and 98%, respectively.
Data Acquisition
The subjects were positioned in a whole body scanner (model CTI 931, Siemens CPS, Knoxville, Ind.). This instrument allows simultaneous acquisition of 15 cross-sectional images (eight direct planes, seven cross planes) with a spatial resolution of 6-8 mm. Transmission scans were acquired for 15 minutes using a retractable germanium-68 ring source. The transmission scans were used for positioning the patient as well as for subsequent attenuation correction of the emission scans.
The imaging protocol consisted of a myocardial blood flow study followed by dynamic PET imaging after [11C]hydroxyephedrine administration. Sixty millicuries of rubidium-82 (82Rb) or 20 mCi [13N]ammonia were used for the determination of regional blood flow distribution. Imaging acquisition was started 60 seconds after the infusion of 82Rb or 3 minutes after the bolus injection of ["N]ammonia. Imaging data were acquired for 10 minutes. Fifteen minutes after the end of 82Rb infusion or 50 minutes after the end of ["3N]ammonia administration, 20 mCi [f1C]hydroxyephedrine was injected as a slow bolus over 30 seconds. Dynamic PET imaging was initiated simultaneously with ['1C]hydroxyephedrine injection. The imaging protocol was six 30-second, two 60-second, two 150second, two 300-second, two 600-second, and one 1,200-second images, for a total data acquisition time of 60 minutes. Heart rate and blood pressure were recorded before ['1C]hydroxyephedrine injection and again every 2 minutes for 10 minutes after tracer injection. The electrocardiogram was continuously monitored throughout the study.
Data Processing and Data Analysis
The data were reconstructed into transverse crosssectional images using filtered back-projection and a Hanning filter with a cutoff frequency of 0.35 per pixel. True cross-sectional images perpendicular to the long axis of the heart were generated with a SUN workstation and customized software (Analyze, Mayo Clinic, Rochester, Minn.).
The relative myocardial distribution of [13N]ammonia or "Rb was evaluated visually to determine the homogeneity of blood flow. In addition, circumferential profile analysis was used to compare regional tracer uptake in our subjects with that of a normal data base. 
98±8 HR, heart rate; SBP, systolic blood pressure; DBP, diastolic blood pressure. Values are given as mean±SD.
Regional [11C]hydroxyephedrine kinetics were determined by placing regions-of-interest over the myocardium and ventricular blood pool. In the transplant patients, the myocardial regions were defined based on blood flow images because of the poor [1WC]hydroxyephedrine uptake in these patients. The selected regions-of-interest were subsequently copied to all image planes, and time-activity curves of blood pool and myocardium were generated. The 1`C activity was normalized to peak blood and myocardial activity and expressed as the percentage of peak blood activity.
In addition, the ventricular`1C activity derived from the last image was normalized to the integral of the blood activity to determine the 1`C retention fraction. The regional tracer retention within the left ventricle was plotted on a polar map, which displays circumferential activity profiles from the base to the apex of the left ventricle. Regional activity was normalized to peak ventricular activity and expressed as the percentage of the peak ventricular activity in normal volunteers.
Statistics
All values are given as mean+SD. Statistical comparisons were performed using Student's t test and linear regression analysis. Ap value of less than 0.05 was considered statistically significant.
Results
All patients tolerated the intravenous bolus injection of ["C]hydroxyephedrine without side effects.
The hemodynamic data before and after tracer injection are reported in Table 1 . There was no significant change in heart rate or blood pressure after the injection of [11C]hydroxyephedrine in the normal volunteers or patients with cardiac transplant.
Regional myocardial blood flow was homogeneous in all individuals studied. There was no evidence of regional perfusion abnormalities. leling the blood flow homogeneity determined by 82Rb distribution. The heart-to-blood and heart-to-lung activity ratios at 30 minutes after tracer injection were 5.0 and 4.2, respectively, in this normal volunteer. Regional tracer distribution was quantified using circumferential profile techniques and shown in relation to maximal myocardial activity using the polar map approach (Figure 2, bottom panel) . This simplified three-dimensional representation of regional tracer retention indicated a homogeneous distribution of`1C within the normal left ventricle, again paralleling the blood flow pattern shown on the left side of Figure 2b . Figure 3 shows time-activity curves obtained from a region-of-interest placed over the left ventricular cavity and myocardium in the same normal volunteer.
1C in the blood cleared rapidly. Myocardial activity initially decreased to about 75% of that at peak uptake, but remained essentially constant for the remainder of the data acquisition. Figure 4 shows cross-sectional short-axis images of the left ventricle of a patient with a recent cardiac transplant after the injection of82Rb and [J'C]hydroxyephedrine. The 82Rb images indicated a homogeneous blood flow distribution. In contrast, regional
[W1C]hydroxyephedrine retention at 30 minutes after tracer injection was markedly reduced compared with that of 12Rb.
The regional time-activity curves obtained from the same cardiac transplant patient from regionsof-interest placed over the myocardium and blood pool are shown in Figure 5 . The blood`1C activity decreased rapidly, in a manner similar to that in the normal population. However, 1`C retention in the myocardium was markedly reduced compared with that in normal volunteers. The tracer retention by the myocardia of all transplant patients was significantly lower from 6 to 60 minutes after tracer injection compared with the control population (Table 2 ). There was no significant difference in the blood 1`C clearance patterns of the transplant patients compared with the control population. Figure 6 shows the myocardial retention by normal volunteers and patients with cardiac transplants of 1C activity at 60 minutes, normalized to the integral and 20 mCi [11Clhydroxyephedrine (C-11 HED) (top). There is homogeneous blood flow and [11C]hydroxyephednine retention at 60 minutes after tracer injection. Note high heartto-blood and heart-to-lung contrasts ofthe C-11 HED images. Bottom panel: Circumferential tracer distibution throughout the left ventricle of a normal volunteer, displayed with the polar map approach. Relative tracer retention in the most apical image plane is projected on center of map. Most basal image plane forms outer boundary. Left map depicts regional blood flow distribution (measured by retention of rubidium-82), whereas regional C-il HED retention is displayed on right. Note homogeneous retention of C-li HED in this normal volunteer. ANT, anterior; SEP, septal; LAT, lateral; INF, inferior. of the arterial input function. The tissue retention percentage of the tracer was 1.6+1.0% in patients with cardiac transplant, compared to 7.0±1.0% in normal volunteers (p<0.001).
Myocardial`1C activity in all volunteers averaged 78% of initial peak myocardial activity at 10 minutes, 80% at 30 minutes, and 79% at 60 minutes after tracer injection. Relative tissue and blood activity at 1, 2, 4, 6, 10, 30, and 60 minutes after tracer administration (normalized to peak blood activity) is reported in Table  2 . In all subjects, there was only 8% of peak blood activity remaining at 10 minutes after injection. Heartto-blood activity ratios exceeded 2 as soon as 4 minutes after the tracer injection and increased to 6.9 by 60 minutes in the normal volunteers (Table 2).
Regional Variation of [>C]Hydroxyephedrine Retention
To determine the regional retention of [("Chydroxyephedrine throughout the normal left ventricle, the relative`1C activity at 60 minutes after tracer injection was averaged in all six normal volunteers, expressed as a percentage of peak myocardial activity, and displayed as an average polar map (Figure 7 ). There was no significant regional change of tracer retention in the circumferential or longitudinal direction in the normal volunteers. Therefore, the physiological information obtainable with ['1C]hydroxyephedrine pertains primarily to the catecholamine uptake and storage capacity of adrenergic nerve terminals. Tissue retention of ["C]hydroxyephedrine correlated closely with the tissue norepinephrine concentrations determined postmortem in a canine model of regional cardiac denervation. 13 The relative decrease of ["C]hydroxyephedrine retention was paralleled by the same degree of norepinephrine depletion, indicating that little non-neuronal binding of this tracer occurred in canine myocardium.
The reported data in the patients with cardiac transplants are similar to these animal data. The retention of ["C]hydroxyephedrine of these subjects was 82% less than that of the normal volunteers. Because the PET images were corrected for photon attenuation, the regional`C activity directly reflects tissue [11C]hydroxyephedrine concentration, allowing quantitative assessment of tracer concentration. The arterial input function derived from regions-of-interest over the left ventricle has been shown to correlate closely with the results of direct arterial blood sampling. 19 Thus, the retained myocardial 1`C activity can be normalized to the arterial input, yielding a quantitative parameter of neuronal ['1C]hydroxyephedrine retention ( Figure 6 ). The calculated myocardial retention fraction of 7% of the arterial input agrees closely with the retention fraction normalized to the injected dose in animal experiments.13 Current research in our laboratory is focusing on the development and validation of a tracer kinetic model for The evaluation of the sympathetic nervous system in the human heart has been limited in the past to invasive methods.7 Measurement of arteriovenous differences in plasma norepinephrine concentrations allows only the indirect assessment of sympathetic nerve activity. More than 70% of norepinephrine released by the sympathetic nerve terminals undergoes reuptake.21 This internal reutilization of norepinephrine cannot be estimated by the measurement of norepinephrine spillover into the venous effluent. Therefore, arteriovenous sampling techniques do not permit differentiation between increased norepinephrine release and decreased reuptake of the neurotransmitter. A recent approach using radiolabeled norepinephrine and analysis of radiolabeled 0-metabolites in the venous effluent has improved the specificity of the invasive methods in the determination of sympathetic nerve activity.7 This technique, however, is limited to the catheterization laboratory and allows only the global evaluation of the cardiac sympathetic nervous system. Therefore, the noninvasive imaging approach using radiolabeled catecholamines appears to be applicable to the clinical evaluation of patients with various heart diseases.
Several experimental studies have indicated the importance of the uptake-1 and subsequent vesicular storage for the removal of norepinephrine from myocardial tissue.21-23 This sequestration process is responsible for the regulation of the extravascular norepinephrine concentration in the myocardium.
Thus, ['1C]hydroxyephedrine may prove to be a valuable tool in the assessment of the capacity of the sympathetic nervous system to remove norepinephrine from myocardial tissue, and may provide a noninvasive means of correlating regional neuronal function with electrophysiological data. Finally, this new tracer approach may allow the study of the pharmacological ANT SEP VOLUNTEERS * pcO.001 * CARDIAC TRANSPLANTS FIGURE 6. Bar graph of carbon-li (C-li) retention fractions (RFs) as determined by the normalization of myocardial 1C activity (`QCtissue) to the integral of the arterial blood activity (Cbd) 60 minutes after tracer injection. RF=C,/suel°Of0 Cbb,d.
LAT INF FIGURE 7. Average polar map of relative regional distribution of blood flow and ['1C]hydroxyephedrine retention at 60 minutes in six normal volunteers. Average regional activity was normalized to peak myocardial activity and expressed as a percentage ofpeak myocardial activity. ANT, anterior; SEP, septal; LAT, lateral; INF, inferior. effects of many cardiovascular drugs on the uptake of norepinephrine by the sympathetic nervous system. However, further careful validation of the efficacy of [t'C]hydroxyephedrine in animal studies is necessary to the development of quantitative techniques for future applications in the clinical environment.
Conclusions
[t1C]Hydroxyephedrine, used in combination with PET, is a new noninvasive approach to the study of the sympathetic nervous system in the human heart. The normal heart is characterized by homogeneous retention of [11C]hydroxyephedrine. The retention of the tracer was markedly lower in patients with recent cardiac transplants than in normal volunteers, indicating the specificity of this tracer and the potential of assessing presynaptic catecholamine uptake by PET imaging. This approach is a promising new dimension of PET imaging and may be useful in the evaluation of the sympathetic nervous system in various disease states such as myocardial infarction, congestive cardiomyopathy, and dysrhythmia.
